CVS innovation: Hyperlipidemia, Heparin and Hemodialysis access failure diseases treatment? Historical deal analysis in CVS and investment opportunity, are you ready?
- Hyperlipidemia, Heparin and Hemodialysis access failure diseases treatment
- CVS field deals and opportunity for investment analysis
- China market front runner in the field of AVF and critical Limb ischemia
- Research Spotlight on a biotech company in Hemodialysis access failure with innovation breakthrough
Event details
|
DATE Thursday October 15, 2020 VENUE Online Webex / Gotomeeting TIME 10am -11am (Berlin time) 4:00 PM - 5:00 PM (Beijing time) RSVP This is a complimentary event VIP tickets priority for Lingmed current clients Please RSVP by October 14, 2020 |
PRESENTERS Lingling Cao, CEO & Founder Dr Hank Wang, Medical advisor Aki Prihti , CEO, from Aplagon Oy REGISTER +86 21 5386 3003 BD@lingmed.net |
Agenda
| CET 10:00 - 10:30 |
|
by Dr Hank Wang (Chinese) |
| CET 10:30 - 10:35 | Linkedbio services & projects introductions | by Lingling Cao (English) |
| CET 10:35 - 10:55 | Research Spotlight on a biotech company in Hemodialysis access failure with innovation breakthrough | by Aki Prihti from Aplagon Oy (English) |
| CET 10:55 – 11:00 | Q&A | (English & Chinese) |
Presenters
 |
Lingling Cao CEO & Founder Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany |
 |
Hank Wang Medical advisor Dr Wang holds a PhD degree on Medicinal Chemistry from Peking University, has a Postdoc experience in University of Missouri-Saint Louis, and worked as a Postdoc Fellow in Auburn University. Hank Wang has more than 10 years’ experience in pharmaceuticals industry. Hank has worked as Vice President and President of R&D at Beijing Haiyan Pharmaceutical Co., Ltd. - Yangtze River Pharmaceutical Group. Dr Wang advises Lingmed on innovative assets evaluation for China market |
 |
Aki Prihti Aplagon Oy Aki Prihti has been the CEO of Aplagon Oy since 2015 and has close to 20 years of experience in setting up, developing, and funding life science growth companies. In addition to Aplagon, Aki serves as Board member of Herantis Pharma Oyj, Medtentia International Ltd Oy, and Aranda Pharma Oy. Aki is also one of the founders of Inveni Capital, a life sciences focused venture capital fund. Aki received his MSc in Economy and Business Administration from Helsinki School of Economics and Business Administration, Finland. |